Health
Australia set to host clinical trial of genetically modified Covid nasal spray vaccine – The Guardian
Australian company applies for permission to conduct trial of men and women aged 18 to 55
Vaccines and immunisationAustralian company applies for permission to conduct trial of men and women aged 18 to 55
Australia is set to host the first human clinical trial of a genetically modified adenovirus vaccine for Covid-19 delivered via nasal spray.
Avance Clinical, an Australian contract research organisation, has applied to the office of the gene technology regulator for permission to conduct the phase 1 clinical trial on behalf US company Tetherex Pharmaceuticals Corporation.
The trial…
-
General18 hours agoAustralia Kangaroos lose Xavier Coates and Zac Lomax ahead of rugby league Ashes in England
-
Business21 hours agoDoes Macquarie rate Karoon Energy shares a buy, hold or sell?
-
Noosa News22 hours agoThree steps Queensland SES want you to know to Get Ready for severe weather
-
Noosa News24 hours agoIn Trent Dalton’s new book Gravity Let Me Go, the bestselling author interrogates himself